September 26, 2023, Chicago, IL: NovaScan, Inc. a clinical stage venture-backed oncology company, announced today that the company has had multiple abstracts accepted in upcoming leading medical conferences around the globe. These conferences include the following:
- American Society of Clinical Oncology
- American Association of Cancer Research: Special Conference on Pancreatic Cancer
- American College of Gastroenterology Annual Meeting
- United European Gastroenterology Annual Meeting
- CHEST Annual Meeting
NovaScan posters discuss clinical evidence of recent innovations in both pancreatic cancer and lung cancer identification and offer the possibility for improved detection and treatment in coming years. Most of them reference studies completed with the company’s new nsCanary™ product. nsCanary is NovaScan’s product for real time detection of cancer biopsies. It is compact, easy to use, and informs clinicians on the presence of cancer in only seconds. NovaScan’s poster at ACG was selected for the Presidential Poster Award. Lead authors include Federica Dibennardo, Les Bogdanowicz PhD, and Isaac Raijman, MD.
“We are excited about the progress we are making in GI and lung areas” remarked Dibennardo, “We are working with leading clinicians, and we think that we can improve cancer diagnosis in multiple areas of medicine.”
NovaScan’s nsCanary product is currently employed in multiple clinical sites around the globe. The company anticipates a pivotal trial to commence late next year.
About NovaScan: Based in Chicago, NovaScan (www.novascaninc.com) is a clinical stage oncology diagnostic and stratification company that has developed a low cost, point of care platform for real time cancer detection and stratification. NovaScan’s platform is active in lung, breast, skin, and GI.